Singh S, Halperin D, Myrehaug S, Herrmann K, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high?dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomise Lancet 2024;403:2807-2817.
PMID: 38851203